AI assistant
Revolution Medicines, Inc. — Director's Dealing 2021
Mar 9, 2021
30695_dirs_2021-03-08_d2662ef9-3182-479a-84e6-ba25b628024b.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Revolution Medicines, Inc. (RVMD)
CIK: 0001628171
Period of Report: 2021-03-04
Reporting Person: Anders Jack (See Remarks)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-03-04 | Common Stock | A | 7400 | — | Acquired | 7904 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2021-03-04 | Stock Option (Right to Buy) | $42.45 | A | 25900 | Acquired | 2031-03-03 | Common Stock (25900) | Direct |
Footnotes
F1: Includes 7,400 Restricted Stock Units.
F2: Includes 504 shares acquired under the Issuer's Employee Stock Purchase Plan on November 30, 2020.
F3: One forty-eighth (1/48th) of the shares initially subject to the option will vest on each monthly anniversary measured from March 4, 2021 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.